Chime Biologics has announced a strategic cooperation agreement with Polpharma Biologics to advance the end-to-end development and manufacture of a biosimilar product for the global market. This partnership underscores Chime Biologics' commitment to delivering high-quality, cost-effective biologics and further strengthening Chime Biologics' presence in Europe.

Under this agreement, Chime Biologics will provide Polpharma Biologics with end-to-end support for a biosimilar development, spanning from investigational new drug (IND) to commercial supply.

Polpharma Biologics, a major player in the global biosimilar market and the largest biotechnology company in Poland, brings a robust pipeline that includes multiple early-stage and late-stage biosimilars, along with two FDA/EMA-approved biosimilar products.

“Chime Biologics is well-positioned to meet the growing global demand for biosimilars. Through Chime's true end-to-end offerings, from our state-of-the-art cell line, process and analytical development capabilities, expanding manufacturing capabilities and regulatory support activities, Chime Biologics offers clients fast-tracked CMC development to commercial supply to ensure fast market entry for our clients,” the company said in a statement.

Dr. Jimmy Wei, President of Chime Biologics said, “We are thrilled to contribute to Polpharma Biologics' growth as we provide all-in-one solutions to accelerate biosimilar development and reduce the time-to-market. This collaboration reinforces our strategy of delivering high-quality, affordable biologics to patients worldwide.”

Konstantin Matentzoglu, Member of the Supervisory Board of Polpharma Biologics Group BV stated, “Partnering with Chime Biologics supports our strategic vision to swiftly bring affordable biosimilars developed in Europe to global markets. By working with Chime Biologics, we can accelerate patient access to biosimilar therapies. This partnership further strengthens Polpharma Biologics' global position as a leading biosimilars developer, while leveraging Asian partners with optimized cost-benefit ratio.”